LOS ANGELES — President-elect Donald Trump’s promise of mass deportations and tougher immigration restrictions is deepening mistrust of the health care system among California’s immigrants and clouding the future for providers serving the state’s most impoverished residents. At the same time, immigrants living illegally in Southern California told KFF Health News they thought the economy…
Many of President-elect Donald Trump’s candidates for federal health agencies have promoted policies and goals that put them at odds with one another or with Trump’s choice to run the Department of Health and Human Services, Robert F. Kennedy Jr., setting the stage for internal friction over public health initiatives. The picks hold different views…
LOS ÁNGELES, California.— La promesa del presidente electo Donald Trump de deportaciones masivas y restricciones migratorias más severas está aumentando la desconfianza en el sistema de salud entre los inmigrantes en California, y nublando el futuro de los proveedores que atienden a los residentes más empobrecidos del estado. Al mismo tiempo, inmigrantes que viven en…
By JEFF GOLDSMITH Healthcare payment in the US has evolved in decades-long sweeps over the past fifty years, as both public programs and employers attempted to contain the rise in health costs. Managed care in the United States has gone through three distinct phases in that time- from physician- and hospital-led HMOs to PPOs and “shadow”…
The Washington Post reports on a meeting between President-elect Trump, Robert F. Kennedy, Jr. and a number of CEOs of pharmaceutical firms. When the topic turned to vaccines, the discussion was not about banning the products, the three people said. Kennedy spoke about the need for better study of the vaccine dosing schedule for newborns…
Neurocrine Biosciences’ Crenessity is now FDA approved for treating classic congenital adrenal hyperplasia (CAH), a rare and potentially fatal endocrine disorder. The approval comes with a priority review voucher, which Neurocrine could sell for around $150 million. The post Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder appeared first…
Ayuda Medical offers a wearable device that can detect an overdose and call for help. The company has received support from the NIH and NIDA via the Small Business Innovation Research program. The post How One Company is Using an Armband to Combat the Overdose Crisis appeared first on MedCity News.
Zocdoc CEO Oliver Kharraz has some predictions about how healthcare will change in 2025 — including the rise of cash-pay services and the potential restructuring of Amazon’s healthcare assets. The post Zocdoc CEO Predicts 3 Ways the Healthcare Industry Will Change in 2025 appeared first on MedCity News.
Joining Matthew Holt on #THCBGang on Monday December 16 at 1pm PST 4pm EST are patient safety expert Michael Millenson, physician, entrepreneur and technologist Shantanu Nundy; and Digital Health and Emerging Med-Tech Practice Co-Founder at Marsh & McLennan, Beracah Stortvedt. You can see the video below live (and later archived) & if you’d rather listen than…
Novo Nordisk’s new Denmark site will produce drugs for rare diseases, such as hemophilias. Separately, the pharma giant said all regulatory conditions have been met for Novo Holdings’ acquisition of Catalent, which will bring to Novo Nordisk three manufacturing sites for GLP-1 medications. The post Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New…